Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 11/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 8/20 | 0.47 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GPR3 | P46089 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30605416 | 1.00 | CYP11B2 (0.47) | CYP11B2CYP11B1PRKCZADRA2AADRA2B | |
| SCHEMBL18805059 | 1.00 | CYP11B2 (0.47) | CYP11B2CYP11B1PRKCZADRA2AADRA2B | |
| Sulfuric Acid SCHEMBL999149 | 0.88 | ERN1 (0.43) | CYP11B2CYP11B1PRKCZADRA2AADRA2B | |
| Sulfuric Acid SCHEMBL31560042 | 0.88 | ERN1 (0.43) | CYP11B2CYP11B1PRKCZADRA2AADRA2B | |
| Sulfuric Acid SCHEMBL31560041 | 0.88 | ERN1 (0.43) | CYP11B2CYP11B1PRKCZADRA2AADRA2B | |
| SCHEMBL28481338 | 0.82 | ALDH1A1 (0.52) | CYP11B2CYP11B1PRKCZADRA2AADRA2B | |
| SCHEMBL20873066 | 0.75 | PRKCZ (0.64) | CYP11B2CYP11B1PRKCZADRA2AADRA2B | |
| SCHEMBL31325680 | 0.74 | EGFR (0.44) | CYP11B2CYP11B1PRKCZADRA2AKDM4E | |
| SCHEMBL31325689 | 0.74 | EGFR (0.44) | CYP11B2CYP11B1PRKCZADRA2AKDM4E | |
| SCHEMBL4207818 | 0.73 | KDM4E (0.59) | CYP11B2CYP11B1PRKCZKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117946002-A | Synthesis method of rosuvastatin key intermediate | 安徽峆一药业股份有限公司 | 2024-04-30 | — | — | CN | claimed |
| CN-112047884-A | Synthesis method of 4-fluoroisoquinoline sulfate | 沈阳市摩尔医药技术开发有限责任公司 | 2020-12-08 | — | — | CN | claimed |
| EP-1852421-B1 | PROCESS FOR PRODUCTION OF 4-FLUOROISOQUINOLINE-5-SULFONYL HALIDE OR SALT THEREOF | KOWA CO (JP) | 2011-05-04 | — | — | EP | claimed |
| US-7872136-B2 | Process for production of 4-fluoroisoquinoline-5-sulfonyl halide or salt thereof | KOWA CO., LTD. (JP) | 2011-01-18 | — | — | US | claimed |
| US-20090209765-A1 | PROCESS FOR PRODUCTION OF 4-FLUOROISOQUINOLINE-5-SULFONYL HALIDE OR SALT THEREOF | KOWA CO., LTD. (JP) | 2009-08-20 | — | — | US | claimed |
| EP-1852421-A1 | PROCESS FOR PRODUCTION OF 4-FLUOROISOQUINOLINE-5-SULFONYL HALIDE OR SALT THEREOF | Kowa Company, Ltd. (JP) | 2007-11-07 | — | — | EP | claimed |
| US-12528774-B2 | Thiosemicarbazone compounds and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-01-20 | — | — | US | disclosed |
| CN-113227054-B | ROCK kinase inhibitors | 切尔韦洛治疗有限责任公司 | 2025-04-11 | — | — | CN | disclosed |
| US-20250100981-A1 | Cis-substituted 5-(hydroxymethyl)morpholine-2-carboxamides as agonists of SSTR4 | BOEHRINGER INGELHEIM INT (DE) | 2025-03-27 | — | — | US | disclosed |
| EP-3838900-B1 | 3-ARYLOXY-3-ARYL-PROPYLAMINE COMPOUND AND USES THEREOF | ZHANGZHOU PIEN TZE HUANG PHARM (CN) | 2025-02-12 | — | — | EP | disclosed |
| EP-3877364-B1 | ROCK KINASE INHIBITORS | Cervello Therapeutics LLC (US) | 2024-08-21 | — | — | EP | disclosed |
| CN-117946002-A | Synthesis method of rosuvastatin key intermediate | 安徽峆一药业股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117946002-A | Synthesis method of rosuvastatin key intermediate | 安徽峆一药业股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| EP-0885888-B1 | ISOQUINOLINE DERIVATIVES AND DRUGS | HIDAKA HIROYOSHI DR (JP) | 2003-08-13 | — | — | EP | disclosed |
| US-6323217-B2 | CARDIOVASCULAR DISORDERS | ADIR ET COMPAGNIE (FR) | 2001-11-27 | — | — | US | disclosed |
| US-20010034352-A1 | Piperidine-4 sulphonamide compounds | LES LABORATOIRES SERVIER (FR) | 2001-10-25 | — | — | US | disclosed |
| EP-1122254-A2 | 4-Sulfonamide piperidine derivatives, method for their preparation and phamaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-08-08 | — | — | EP | disclosed |
| EP-1074545-A1 | ISOQUINOLINESULFONAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | Hidaka, Hiroyoshi (JP) | 2001-02-07 | — | — | EP | disclosed |
| US-6153608-A | Isoquinoline derivatives and drugs | NIPPON SHINYAKU CO., LTD. (JP) | 2000-11-28 | — | — | US | disclosed |
| EP-0885888-A1 | ISOQUINOLINE DERIVATIVES AND DRUGS | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1998-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034352-A1 | Piperidine-4 sulphonamide compounds | KDR, GLS, FLT1 | CYP11B2 262/4885CYP11B1 244/4885PRKCZ 679/4885 |
| US-12528774-B2 | Thiosemicarbazone compounds and uses thereof | SCN2B, SCN1B, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CYP11B2 568/4885CYP11B1 644/4885PRKCZ 868/4885 |
| US-20250100981-A1 | Cis-substituted 5-(hydroxymethyl)morpholine-2-carboxamides as agonists of SSTR4 | SSTR4, SSTR5, SSTR2 | CYP11B2 499/4885CYP11B1 816/4885PRKCZ 3023/4885 |
| US-20090209765-A1 | PROCESS FOR PRODUCTION OF 4-FLUOROISOQUINOLINE-5-SULFONYL HALIDE OR SALT THEREOF | SALL4, STS, SFPQ | CYP11B2 1226/4885CYP11B1 1706/4885PRKCZ 3015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.